Metachromatic Leukodystrophy Treatment and Diagnosis Strategies

Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disorder arising from deficient activity of the enzyme arylsulfatase A (ARSA). This defect leads to progressive accumulation of sulphated glycosphingolipids (sulfatides) in the central and peripheral nervous systems, precipitating widespread demyelination, motor and cognitive decline, and early mortality. Diagnostic strategies increasingly combine genetic, biochemical and imaging approaches: high-throughput enzyme assays and genotype–phenotype matrices refine risk prediction and resolve variants of unknown significance, while urinary sulfatide profiling and advanced magnetic resonance imaging scoring systems bolster early detection and monitoring. Therapeutic options have evolved beyond allogeneic haematopoietic cell transplantation (HCT) to encompass gene-cell therapies, intrathecal enzyme replacement and small-molecule interventions. Early pre-symptomatic intervention remains the cornerstone of improved outcomes, with newborn screening initiatives and rapid molecular diagnostics enabling timely delivery of curative or stabilising treatments. Despite these advances, challenges persist in targeting peripheral neuropathy, achieving durable central nervous system enzyme delivery and managing treatment-related immune complications. Ongoing research seeks to optimise vector design, dosing regimens and combinatorial strategies to extend benefit across all MLD subtypes and stages.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Metachromatic Leukodystrophy Treatment and Diagnosis Strategies publication trend

The graph below shows the total number of articles in metachromatic leukodystrophy treatment and diagnosis strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Arylsulfatase A (ARSA): A lysosomal hydrolase enzyme that degrades sulfatides; its deficiency underlies the biochemical basis of MLD.

Sulfatides: Sulphated glycolipids that constitute essential components of myelin; their pathological accumulation in MLD triggers demyelination.

Hematopoietic stem cell gene therapy (HSCGT): A therapeutic modality in which a patient’s own stem cells are genetically modified to express functional ARSA, aiming to restore enzyme activity through engraftment and cross-correction.

Newborn screening (NBS): Population-level testing performed shortly after birth to detect ARSA deficiency before symptom onset, facilitating early therapeutic intervention.

References

1. Predicting disease severity in metachromatic leukodystrophy using protein activity and a patient phenotype matrix. Genome Biology (2023).
2. Lentivirus-modified hematopoietic stem cell gene therapy for advanced symptomatic juvenile metachromatic leukodystrophy: a long-term follow-up pilot study. Protein & Cell (2024).
3. Profiling and semi-quantitation of urine sulfatides by UHPLC-Orbitrap-HRMS. Analytica Chimica Acta (2025).
4. Metachromatic Leukodystrophy: Diagnosis, Modeling, and Treatment Approaches. Frontiers in Medicine (2020).
5. Peripheral neuropathy in metachromatic leukodystrophy: current status and future perspective. Orphanet Journal of Rare Diseases (2019).
6. Metachromatic Leukodystrophy: A Scoring System for Brain MR Imaging Observations. American Journal of Neuroradiology (2009).
7. Safety of intrathecal delivery of recombinant human arylsulfatase A in children with metachromatic leukodystrophy: Results from a phase 1/2 clinical trial. Molecular Genetics and Metabolism (2020).